1
/
of
3
3MGS
Gardasil®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Gardasil®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Regular price
$8,705.35 USD
Regular price
Sale price
$8,705.35 USD
Shipping calculated at checkout.
Quantity
Couldn't load pickup availability
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is a breakthrough immunization designed to protect against nine strains of human papillomavirus (HPV), offering comprehensive protection against HPV-related cancers and precancerous lesions.
For women aged 9–45 years, GARDASIL 9 prevents cervical, vulvar, vaginal, anal, oropharyngeal, and head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. It also guards against precancerous lesions and genital warts caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
For men aged 9–45 years, the vaccine prevents anal, oropharyngeal, and head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58, as well as precancerous anal lesions and genital warts from HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
The vaccine's oropharyngeal and head and neck cancer indication has been approved under accelerated approval based on proven effectiveness in preventing HPV-related anogenital disease.
GARDASIL 9 does not eliminate the need for regular cancer screenings as recommended by healthcare providers, nor does it treat existing cancers, precancerous lesions, or genital warts. Protection is limited to HPV types covered by the vaccine and does not extend to previously acquired HPV exposures.
Common side effects include injection-site pain, swelling, erythema, and headache. Administration follows a 2-dose schedule for ages 9–14 or a 3-dose schedule for ages 15–45, delivered intramuscularly in the deltoid or anterolateral thigh.
Available from THOG Pharmacy Co, your trusted source for preventive health solutions across the Philippines.
For women aged 9–45 years, GARDASIL 9 prevents cervical, vulvar, vaginal, anal, oropharyngeal, and head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. It also guards against precancerous lesions and genital warts caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
For men aged 9–45 years, the vaccine prevents anal, oropharyngeal, and head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58, as well as precancerous anal lesions and genital warts from HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
The vaccine's oropharyngeal and head and neck cancer indication has been approved under accelerated approval based on proven effectiveness in preventing HPV-related anogenital disease.
GARDASIL 9 does not eliminate the need for regular cancer screenings as recommended by healthcare providers, nor does it treat existing cancers, precancerous lesions, or genital warts. Protection is limited to HPV types covered by the vaccine and does not extend to previously acquired HPV exposures.
Common side effects include injection-site pain, swelling, erythema, and headache. Administration follows a 2-dose schedule for ages 9–14 or a 3-dose schedule for ages 15–45, delivered intramuscularly in the deltoid or anterolateral thigh.
Available from THOG Pharmacy Co, your trusted source for preventive health solutions across the Philippines.
Share
